Ting Wan-Hua, Chen Hui-Hua, Wei Ming-Chow, Sun Hsu-Dong, Hsiao Sheng-Mou
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220216, Taiwan.
Department of Electrical Engineering, Yuan Ze University, Taoyuan 320315, Taiwan.
Cancers (Basel). 2024 Oct 3;16(19):3382. doi: 10.3390/cancers16193382.
To compare the clinical outcomes of intravenous carboplatin/paclitaxel chemotherapy plus bevacizumab versus intraperitoneal cisplatin/paclitaxel chemotherapy without bevacizumab as the frontline treatment in women with advanced ovarian, fallopian tube and primary peritoneal cancer. Between November 2012 and January 2024, medical records of all consecutive women with stage II~IV cancer treated with either frontline adjuvant intraperitoneal cisplatin/paclitaxel without bevacizumab (IP group), intravenous carboplatin/paclitaxel without bevacizumab (IV group) or intravenous carboplatin/paclitaxel with bevacizumab (IVB group) at a tertiary referral center were reviewed. A total of 143 women (IP group, n = 57; IVB group, n = 23; IV group, n = 63) were reviewed. The IP group had greater progression-free survival compared to the IVB group (49.1 months, 95% confidence interval [CI] = 27.8 months to infinity, versus 11.9 months, 95% CI = 11.2 to 16.2 months; adjusted hazard ratio [HR] = 0.45, 95% CI = 0.24 to 0.87, = 0.017). Additionally, the IP group also had a higher overall survival compared to the IVB group (not reached, 95% CI = 55.6 months to infinity, versus 38.9 months, 95% CI = 21.9 months to infinity; adjusted HR = 0.34, 95% CI = 0.15 to 0.79, = 0.012). Intraperitoneal cisplatin/paclitaxel chemotherapy without bevacizumab seems to offer a survival advantage when compared with intravenous carboplatin/paclitaxel with bevacizumab in the frontline treatment of women with advanced ovarian cancer.
比较静脉注射卡铂/紫杉醇化疗联合贝伐单抗与不使用贝伐单抗的腹腔内顺铂/紫杉醇化疗作为晚期卵巢癌、输卵管癌和原发性腹膜癌女性一线治疗的临床疗效。2012年11月至2024年1月，回顾了一家三级转诊中心所有连续接受一线辅助腹腔内顺铂/紫杉醇不联合贝伐单抗（腹腔内化疗组）、静脉注射卡铂/紫杉醇不联合贝伐单抗（静脉化疗组）或静脉注射卡铂/紫杉醇联合贝伐单抗（静脉-贝伐单抗化疗组）治疗的II~IV期癌症女性的病历。共回顾了143名女性（腹腔内化疗组，n = 57；静脉-贝伐单抗化疗组，n = 23；静脉化疗组，n = 63）。腹腔内化疗组与静脉-贝伐单抗化疗组相比，无进展生存期更长（49.1个月，95%置信区间[CI] = 27.8个月至无穷大， versus 11.9个月，95% CI = 11.2至16.2个月；校正风险比[HR] = 0.45，95% CI = 0.24至0.87，P = 0.017）。此外，腹腔内化疗组与静脉-贝伐单抗化疗组相比，总生存期也更高（未达到，95% CI = 55.6个月至无穷大， versus 38.9个月，95% CI = 21.9个月至无穷大；校正HR = 0.34，95% CI = 0.15至0.79，P = 0.012）。在晚期卵巢癌女性的一线治疗中，不使用贝伐单抗的腹腔内顺铂/紫杉醇化疗与使用贝伐单抗的静脉注射卡铂/紫杉醇化疗相比，似乎具有生存优势。
